Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities.
Cerebral deposition of fibrils formed from the beta/A4 amyloid protein is an invariable feature of Alzheimer's disease. Evidence suggests that generation of such fibrils may be involved in the etiology of this disease, since mutations in the coding region of the beta/A4 amyloid precursor protein (APP) gene segregate with familial cerebral amyloidoses, including familial Alzheimer's disease. Transgenic models of cerebral amyloidosis have been produced, and some progress has been made in elucidating the cell biology of amyloidogenesis. For example, agents that alter protein phosphorylation are potent modulators of the expression and proteolytic processing of APP. Sam Gandy and Paul Greengard review these recent studies, and discuss those that may provide rational therapeutic opportunities.
Gandy
S
S
Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, New York, New York 10021.
Greengard
P
P
D000544:Alzheimer Disease / Q000235:genetics* / Q000628:therapy; D016229:Amyloid beta-Peptides / Q000378:metabolism; D016564:Amyloid beta-Protein Precursor / Q000235:genetics / Q000378:metabolism; D000686:Amyloidosis / Q000235:genetics*; D000818:Animals; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D010766:Phosphorylation
D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor